Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
Wugen has raised $115.0M in total funding. The most recent round was Series C. The last funding was announced in August 2025.
Wugen's investors include Alpha Wave Global, Sands Capital Ventures, Fidelity, Intermediate Capital Group, Abingworth.
Wugen is headquartered in St Louis, United States.
Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
Wugen is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Wugen — Funding & Investors." VCBacked, August 27, 2025, https://www.vcbacked.co/company/wugen. Accessed July 20, 2026.
VCBacked. (2025). Wugen — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/wugen
{{cite web |title=Wugen — Funding & Investors |url=https://www.vcbacked.co/company/wugen |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated